Evidence map›Paper›PMID 40251643›Full record

ArticleStem cell research & therapy2025

Extracellular vesicles from hiPSC-derived NSCs protect human neurons against Aβ-42 oligomers induced neurodegeneration, mitochondrial dysfunction and tau phosphorylation.

Shama Rao, Leelavathi N Madhu, Roshni Sara Babu, Goutham Shankar, Sanya Kotian, Advaidhaa Nagarajan, Raghavendra Upadhya, Esha Narvekar, James J Cai, Ashok K Shetty

Abstract read
In one paragraph

Article in Stem cell research & therapy, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
18citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

18 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Review
  3. Review
  4. Review
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Review
  11. Review
  12. Article
  13. Article
  14. Review
  15. Article
  16. Review
  17. Review
  18. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

10 authors.

Shama RaoInstitute for Regenerative Medicine, Department of Cell Biology and Genetics, College of Medicine, Texas A&M University Health Science Center, College Station, TX, USA.
Leelavathi N MadhuInstitute for Regenerative Medicine, Department of Cell Biology and Genetics, College of Medicine, Texas A&M University Health Science Center, College Station, TX, USA.
Roshni Sara BabuInstitute for Regenerative Medicine, Department of Cell Biology and Genetics, College of Medicine, Texas A&M University Health Science Center, College Station, TX, USA.
Goutham ShankarInstitute for Regenerative Medicine, Department of Cell Biology and Genetics, College of Medicine, Texas A&M University Health Science Center, College Station, TX, USA.
Sanya KotianInstitute for Regenerative Medicine, Department of Cell Biology and Genetics, College of Medicine, Texas A&M University Health Science Center, College Station, TX, USA.
Advaidhaa NagarajanInstitute for Regenerative Medicine, Department of Cell Biology and Genetics, College of Medicine, Texas A&M University Health Science Center, College Station, TX, USA.
Raghavendra UpadhyaInstitute for Regenerative Medicine, Department of Cell Biology and Genetics, College of Medicine, Texas A&M University Health Science Center, College Station, TX, USA.
Esha NarvekarInstitute for Regenerative Medicine, Department of Cell Biology and Genetics, College of Medicine, Texas A&M University Health Science Center, College Station, TX, USA.
James J CaiDepartment of Veterinary Integrative Biosciences, Texas A&M College of Veterinary Medicine, College Station, TX, USA.
Ashok K ShettyInstitute for Regenerative Medicine, Department of Cell Biology and Genetics, College of Medicine, Texas A&M University Health Science Center, College Station, TX, USA. ash.shetty@tamu.edu.ORCID http://orcid.org/0000-0001-5049-6671

Funding

Mesenchymal Stem Cell Derived Extracellular Vesicles for Traumatic Brain InjuryR01NS106907 · NINDS · TEXAS A&M UNIVERSITY HEALTH SCIENCE CTR · PI ASHOK K SHETTY · 2018 to 2026
$4.0M
Intranasal Treatment of Stem Cell-derived Extracellular Vesicles for Alzheimer's DiseaseRF1AG074256 · NIA · TEXAS A&M UNIVERSITY HEALTH SCIENCE CTR · PI SHETTY, ASHOK K · 2022 to 2025
$3.6M
Neural Stem Cell-derived EVs for Improving Aged Brain FunctionR01AG075440 · NIA · TEXAS A&M UNIVERSITY HEALTH SCIENCE CTR · PI ASHOK K SHETTY · 2022 to 2026
$2.9M
NIA NIH HHS 1RF1AG074256-01NIA NIH HHS R01 AG075440NIA NIH HHS R01AG075440-01NIA NIH HHS RF1 AG074256NINDS NIH HHS R01 NS106907
6 · The paper itself

Abstract

backgroundAlzheimer's disease (AD) is characterized by the accumulation of amyloid beta-42 (Aβ-42) in the brain, causing various adverse effects. Thus, therapies that reduce Aβ-42 toxicity in AD are of great interest. One promising approach is to use extracellular vesicles from human induced pluripotent stem cell-derived neural stem cells (hiPSC-NSC-EVs) because they carry multiple therapeutic miRNAs and proteins capable of protecting neurons against Aβ-42-induced toxicity. Therefore, this in vitro study investigated the proficiency of hiPSC-NSC-EVs to protect human neurons from Aβ-42 oligomers (Aβ-42o) induced neurodegeneration.

methodsWe isolated hiPSC-NSC-EVs using chromatographic methods and characterized their size, ultrastructure, expression of EV-specific markers and proficiency in getting incorporated into mature human neurons. Next, mature human neurons differentiated from two different hiPSC lines were exposed to 1 µM Aβ-42o alone or with varying concentrations of hiPSC-NSC-EVs. The protective effects of hiPSC-NSC-EVs against Aβ-42o-induced neurodegeneration, oxidative stress, mitochondrial dysfunction, impaired autophagy, and tau phosphorylation were ascertained using multiple measures and one-way ANOVA with Newman-Keuls multiple comparisons post hoc tests.

resultsA significant neurodegeneration was observed when human neurons were exposed to Aβ-42o alone. Neurodegeneration was associated with (1) elevated levels of reactive oxygen species (ROS), mitochondrial superoxide, malondialdehyde (MDA) and protein carbonyls (PCs), (2) increased expression of proapoptotic Bax and Bad genes and proteins, and genes encoding mitochondrial complex proteins, (3) diminished mitochondrial membrane potential and mitochondria, (4) reduced expression of the antiapoptotic gene and protein Bcl-2, and autophagy-related proteins, and (5) increased phosphorylation of tau. However, the addition of an optimal dose of hiPSC-NSC-EVs (6 × 10

conclusionsAn optimal dose of hiPSC-NSC-EVs could significantly decrease the degeneration of human neurons induced by Aβ-42o. The results support further research into the effectiveness of hiPSC-NSC-EVs in AD, particularly their proficiency in preserving neurons and slowing disease progression.

Indexed as

Amyloid beta-PeptidesExtracellular VesiclesInduced Pluripotent Stem CellsMitochondriaNeural Stem CellsNeuronsPeptide Fragmentstau ProteinsAutophagyCell DifferentiationHumansPhosphorylationAmyloid beta-Peptidesamyloid beta-protein (1-42)Peptide Fragmentstau ProteinsAlzheimer’s diseaseApoptosisAutophagyAβ-42 oligomersMitochondrial dysfunctionNeural stem cellsNeurotoxicityOxidative stressStem cell-derived extracellular vesicles

Identifiers

PMID40251643
PMCPMC12008877

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.